Magnetic Susceptibility from Quantitative Susceptibility Mapping Can Differentiate New Enhancing from Nonenhancing...

Area of Science:

• Neuroimaging
• Magnetic Resonance Imaging (MRI)
• Quantitative Susceptibility Mapping (QSM)

Background:

• Multiple sclerosis (MS) lesion activity is often monitored using MRI with gadolinium contrast.
• Gadolinium-enhancing lesions indicate active inflammation and blood-brain barrier (BBB) leakage.
• Changes in magnetic susceptibility values correlate with lesion evolution.

Purpose of the Study:

• To determine if quantitative susceptibility mapping (QSM) can identify gadolinium-enhancing lesions in MS without gadolinium injection.
• To assess the diagnostic accuracy of QSM for differentiating enhancing from non-enhancing MS lesions.

Main Methods:

• Retrospective analysis of MRI data from 54 MS patients.
• Measurement of magnetic susceptibility values in new T2-weighted lesions using QSM.
• Comparison of QSM values between gadolinium-enhancing and non-enhancing lesions.
• Receiver operating characteristic (ROC) analysis to evaluate diagnostic performance.

Main Results:

• Gadolinium-enhancing lesions exhibited significantly lower relative susceptibility values compared to non-enhancing lesions (β = -17.2, P < .0001).
• QSM demonstrated high diagnostic accuracy in distinguishing enhancing from non-enhancing lesions, with an area under the ROC curve of 0.95.
• Sensitivity was 88.4% and specificity was 91.5% at a cutoff of 11.2 ppb for QSM-measured susceptibility.

Conclusions:

• Quantitative susceptibility mapping (QSM) can accurately identify blood-brain barrier leakage in new T2-weighted lesions in MS patients.
• QSM offers a gadolinium-free method for assessing lesion activity during routine MRI surveillance.
• This technique can aid in monitoring disease activity and treatment response in multiple sclerosis.